Latest Artificial Intelligence News

Vection Technologies reports a record quarter-to-date cash intake of approximately $14 million and a robust $50 million forward pipeline, underscoring strong momentum across defence, AI, healthcare, and retail sectors.

4DMedical has locked in $30.2 million through an underwriting agreement ensuring full exercise of its listed options, lifting its cash reserves to $63.7 million and setting the stage for a pivotal year in commercialising its CT – VQ™ technology.

Tivan Limited has restarted fieldwork at its Sandover AI Project in central Australia, leveraging AI-driven targeting alongside enhanced collaboration with EARTH AI. Results from new electromagnetic surveys are expected by March 2026, setting the stage for expanded drilling campaigns.

Nanoveu’s subsidiary EMASS has teamed up with Semtech to integrate ultra-low-power AI with long-range LoRa connectivity, promising smarter, battery-efficient IoT devices for industrial and smart city applications.

DigiCo Infrastructure REIT appoints Michael Juniper as CEO, signaling a strategic push into advanced data centre development amid rising cloud and AI demand. Chris Maher shifts focus to government relations, underscoring regulatory challenges ahead.

NEXTDC has inked a Memorandum of Understanding with OpenAI to develop a cutting-edge sovereign AI infrastructure in Sydney, marking a major step in Australia’s digital sovereignty ambitions.

Pathkey.AI Ltd has announced a pro rata non-renounceable rights issue to raise approximately $920,517, alongside a $2.5 million placement, aiming to fund enhancements to its AI platform and strategic expansion.

BrainChip Holdings has closed its Share Purchase Plan with subscriptions exceeding the $2 million target by nearly $1 million, complementing a recent $35 million placement. The Board’s decision to accept all applications reflects robust shareholder confidence.

Verbrec Limited has completed a transformative acquisition of Alliance Automation, significantly expanding its digital capabilities and service footprint across Australia and New Zealand.

Imagion Biosystems is set to submit its Investigational New Drug application for the MagSense® HER2 breast cancer imaging agent in December 2025, paving the way for a Phase 2 clinical trial in early 2026. Collaboration with Wayne State University has refined the trial design, promising improved patient safety and diagnostic precision.

Prime Financial Group has reported robust FY25 results, doubling its revenue run rate and expanding its high-net-worth client base through strategic acquisitions. The company sets ambitious growth targets for FY26 and beyond, underpinned by technology investments and leadership enhancements.

NRW Holdings capped FY25 with strong financials and a strategic acquisition, setting the stage for an optimistic FY26. The addition of Fredon Industries expands NRW’s footprint and diversifies its service pillars amid challenging market conditions.